NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Annovis Bio's Buntanetap Shows Cognitive Improvement in Parkinson's Patients with Amyloid Co-Pathology
TL;DR
Annovis Bio's buntanetap offers a competitive advantage by potentially treating multiple neurodegenerative diseases, positioning the company as a leader in broad-acting cognitive therapies.
Buntanetap works by targeting multiple toxic proteins like pTau217 and total tau, reducing biomarkers associated with Alzheimer's pathology across Parkinson's and Alzheimer's disease biology.
This treatment makes the world better by halting cognitive decline in Parkinson's patients and potentially improving quality of life for millions suffering from neurodegenerative diseases.
Annovis Bio's drug reversed cognitive decline in Parkinson's patients with mild dementia, showing strongest benefits in those typically experiencing faster deterioration.
Found this article helpful?
Share it with your network and spread the knowledge!
Buntanetap halted cognitive decline across all patients in the Phase 3 early Parkinson's disease study and delivered the strongest benefit in patients with mild dementia and amyloid co-pathology, reversing cognitive deterioration in this subgroup.
Patients with mild dementia and amyloid co-pathology, representing about 25% of the study population, showed the strongest benefit, with buntanetap reversing their cognitive decline despite typically experiencing faster deterioration.
Treatment with buntanetap produced measurable reductions in pTau217, total tau and brain-derived tau—biomarkers associated with Alzheimer's pathology.
The data reinforce that neurodegenerative diseases often overlap and require therapies capable of targeting multiple toxic proteins, positioning buntanetap as a potentially broad-acting treatment for cognitive impairment across Parkinson's and Alzheimer's disease biology.
Buntanetap is currently in Phase 3 clinical development for early Parkinson's disease.
Annovis Bio is headquartered in Malvern, Pennsylvania and is dedicated to addressing neurodegeneration in diseases such as Alzheimer's disease and Parkinson's disease.
Investors can access the latest news and updates relating to ANVS in the company's newsroom at https://ibn.fm/ANVS and visit www.annovisbio.com for more information.
Buntanetap appears to work by targeting multiple toxic proteins simultaneously, making it potentially effective across different neurodegenerative diseases that often share overlapping pathology, rather than targeting a single disease mechanism.
Curated from InvestorBrandNetwork (IBN)
